NASDAQ
26.76USD
-0.79 (-2.87%)
We have scored 19 news catalysts on Zenas BioPharma, Inc. (ZBIO) over the past 12 months. The biggest single-day move next to one of them came Jan 5, 2026, when ZBIO closed −51.9%: “Dow Jones Today: Stock Futures Point Higher After US Captures Venezuelan President Maduro; Energy Shares, Precious Metals Jump”. Coverage across the window leans mixed (average ticker sentiment −0.07). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7B
P/E
—
EPS
—
Beta
-1.02
52W range
13.5-44.6
Day range
26.18–27.54
Open
27.30
Prev close
27.55
Volume
440.6K
Avg volume
782.8K
Dividend
0.00
IPO
2024-09-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Zenas BioPharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ZBIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
